FIELD: chemistry; biochemistry.
SUBSTANCE: invention relates to genetic engineering and virology. The expression vector for cloning Class I viral fusion protein gene contains Coronavirus M protein gene, Coronavirus E protein gene, IRES site, a first eukaryotic promoter linked to the M protein gene, Coronavirus Spike gene and MCS site and a second eukaryotic promoter linked to the Spike gene.
EFFECT: vector can be used as DNA vaccine candidate against virus infection diseases.
18 cl, 1 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
ARTIFICIAL ECTOS_SC2 GENE ENCODING AN ECTODOMAIN OF THE SARS-COV-2 CORONAVIRUS S GLYCOPROTEIN WITH A C-TERMINAL TRIMERIZATION DOMAIN, A RECOMBINANT PLASMID PSTEM-RVSV-ECTOS_SC2, WHICH PROVIDES EXPRESSION OF THE ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-ECTOS_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733834C1 |
ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
ARTIFICIAL GENE STBL_RBD_TRM_SC2, CODING A BICISTRONIC STRUCTURE FORMED BY THE SARS-COV-2 CORONAVIRUS GLYCOPROTEIN S RECEPTOR-BINDING DOMAIN SEQUENCES, TRANSMEMBRANE REGION, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_TRM_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_TRM_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733832C1 |
METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
PRODUCTION OF VIRUS-LIKE PARTICLES IN PLANTS | 2011 |
|
RU2655431C2 |
DNA VACCINE AGAINST SARS-COV-2 VIRUS BASED ON GENE THERAPY DNA VECTOR GDTT1.8NAS12, METHOD FOR ITS PREPARATION, STRAINS CARRYING GENE-THERAPY DNA VECTORS, METHOD FOR THEIR PREPARATION, METHOD FOR PRODUCTION ON INDUSTRIAL SCALE OF GENE-THERAPY DNA VECTORS | 2020 |
|
RU2759227C2 |
Authors
Dates
2010-03-10—Published
2004-11-26—Filed